Viewing Study NCT01436695


Ignite Creation Date: 2025-12-24 @ 1:33 PM
Ignite Modification Date: 2025-12-28 @ 12:02 PM
Study NCT ID: NCT01436695
Status: UNKNOWN
Last Update Posted: 2011-09-20
First Post: 2011-09-17
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Safety and Feasibility of Using Epicall for Monitoring Pre-seizure Biomarkers
Sponsor: Epicall LTD
Organization:

Study Overview

Official Title: Safety and Feasibility of Using Epicall for Monitoring Pre-seizure Biomarkers
Status: UNKNOWN
Status Verified Date: 2011-09
Last Known Status: NOT_YET_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Epilepsy is a syndrome of episodic brain dysfunction characterized by recurrent seemingly unpredictable spontaneous seizures. The occurrence of the seizure in patients without any forewarning is the most debilitating aspect of the disease.

The Epicall system is intended for early detection of seizure related life threatening events by monitoring per-seizures biomarkers. The system is based on a sticker placed on the side of the face. The external sticker incorporates EOG (electrooculograph electrode) and PPG (photoplethysmograph electrode) sensors for continuous monitoring of:

1. Heart Rate (base line, increase, decrease, asystole).
2. Extra ocular eye movement (blinking, eye deviation, roving eye movements).
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: